Pharmacovigilance in hospice/palliative care: net effect of haloperidol for nausea or vomiting
Digges, Madeline; Hussein, Akram; Wilcock, Andrew; Crawford, Gregory B.; Boland, Jason W.; Agar, Meera R.; Sinnarajah, Aynharan; Currow, David C.; Johnson, Miriam J.
Gregory B. Crawford
Jason W. Boland
Meera R. Agar
David C. Currow
Miriam J. Johnson
Background: Haloperidol is widely prescribed as an antiemetic in patients receiving palliative care, but there is limited evidence to support and refine its use.
Objective: To explore the immediate and short-term net clinical effects of haloperidol when treating nausea and/or vomiting in palliative care patients.
Design: A prospective, multicenter, consecutive case series.
Setting/Subjects: Twenty-two sites, five countries: consultative, ambulatory, and inpatient services.
Measurements: When haloperidol was started in routine care as an antiemetic, data were collected at three time points: baseline; 48 hours (benefits); day seven (harms). Clinical effects were assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE).
Results: Data were collected (May 2014–March 2016) from 150 patients: 61% male; 86% with cancer; mean age 72 (standard deviation 11) years and median Australian-modified Karnofsky Performance Scale 50 (range 10–90). At baseline, nausea was moderate (88; 62%) or severe (11; 8%); 145 patients reported vomiting, with a baseline NCI CTCAE vomiting score of 1.0. The median (range) dose of haloperidol was 1.5 mg/24 hours (0.5–5 mg/24 hours) given orally or parenterally. Five patients (3%) died before further data collection. At 48 hours, 114 patients (79%) had complete resolution of their nausea and vomiting, with greater benefit seen in the resolution of nausea than vomiting. At day seven, 37 (26%) patients had a total of 62 mild/moderate harms including constipation 25 (40%); dry mouth 13 (21%); and somnolence 12 (19%).
Conclusions: Haloperidol as an antiemetic provided rapid net clinical benefit with low-grade, short-term harms.
|Journal Article Type||Article|
|Publication Date||Jan 1, 2018|
|Journal||Journal of Palliative Medicine|
|Publisher||Mary Ann Liebert|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Digges, M., Hussein, A., Wilcock, A., Crawford, G. B., Boland, J. W., Agar, M. R., …Johnson, M. J. (2018). Pharmacovigilance in hospice/palliative care: net effect of haloperidol for nausea or vomiting. Journal of Palliative Medicine, 21(1), doi:10.1089/jpm.2017.0159|
|Keywords||Haloperidol; Nausea; Palliative care; Pharmacovigilance; Symptom control; Vomiting|
|Copyright Statement||Copyright information regarding this work can be found at the following address: http://eprints.nottingh.../end_user_agreement.pdf|
|Additional Information||© 2018 Mary Ann Liebert, Inc. publishers All rights reserved. Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/10.1089/jpm.2017.0159|
Haloperidol accepted version.pdf
Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf
You might also like
A prospective study examining cachexia predictors in patients with incurable cancer